earnings
confidence high
sentiment negative
materiality 0.75
Medline Q4 net income down 37.7% to $180M; FY25 EBITDA up 3.2%; guides FY26 organic sales growth 8-9%
Medline Inc.
2025-FY EPS reported
-$0.01
revenue$28,432,000,000
- Q4 net sales $7.8B (+14.8% YoY); net income $180M (-37.7%); Adj. EBITDA $805M (flat).
- FY25 net sales $28.4B (+11.5%); net income $1.2B (-3.6%); Adj. EBITDA $3.5B (+3.2%).
- FY25 organic sales growth 10.5%; net cash from ops $1.7B; Free Cash Flow $1.3B.
- FY26 guidance: organic sales growth 8-9%; Adj. EBITDA $3.5-3.6B.
- Margins pressured by tariffs and higher costs; $2.4B in new customer signings in 2025.